Pargluva Fluid Retention, Cardiac Risk To Be Central Issues At Advisory Committee

Data showing heart failure rates with 5 mg dose of muraglitazar may be higher than with 30 mg pioglitazone (Lilly/Takeda's Actos) in type 2 diabetes patients will be presented to committee at Sept. 9 review.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet